IP Library Granted Patent US 10,624,870
Granted Patent B2
US 10,624,870 · App. 16/284,543 · Granted Apr 21, 2020

Methods of treating mixed dyslipidemia

Inventors: Ian Osterloh (Kent, GB); Pierre Wicker (Mystic, CT); Rene Braeckman (Richboro, PA); Paresh Soni (Mystic, CT); Mehar Manku (Birmingham, GB)
Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
A61K31/202A61K9/48A61K31/222A61K31/232A61K31/40A61K31/505A61K45/06A61K47/22A61K47/26A61K47/34A61K31/74A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,624,870
App. No.
16/284,543
Granted
Apr 21, 2020
Kind
B2
Abstract

The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.

Claims (11)

1. A method of treating hypertriglyceridemia in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid and docosapentaenoic acid, wherein the eicosapentaenoic acid is present in an amount of about 60% to about 90%, by weight, of all fatty acids present in the pharmaceutical composition and the docosapentaenoic acid is present in an amount of up to about 20%, by weight, of all fatty acids in the pharmaceutical composition, and wherein the pharmaceutical composition comprises substantially no or no docosahexaenoic acid.

2. The method of claim 1 , wherein the eicosapentaenoic acid is present in an amount of about 70% to about 90%, by weight, of all fatty acids present in the pharmaceutical composition.

3. The method of claim 1 , wherein the docosapentaenoic acid is present in an amount up to about 10%, by weight, of all fatty acids present in the pharmaceutical composition.

4. The method of claim 3 , wherein the docosapentaenoic acid is present in an amount up to about 5%, by weight, of all fatty acids present in the pharmaceutical composition.

5. The method of claim 4 , wherein the docosapentaenoic acid is present in an amount of about 5%, by weight, of all fatty acids present in the pharmaceutical composition.

6. The method of claim 1 , wherein the pharmaceutical composition is encapsulated in a capsule shell.

7. The method of claim 1 , wherein the pharmaceutical composition comprises eicosapentaenoic acid in an amount of about 750 mg to about 950 mg.

8. The method of claim 4 , wherein the pharmaceutical composition is encapsulated in a capsule shell.

9. The method of claim 1 , wherein the pharmaceutical composition comprises eicosapentaenoic acid in an amount of about 750 mg to about 950 mg.

10. The method of claim 4 , wherein about 2 g to about 4 g of the pharmaceutical composition is administered to the subject per day.

11. A method of treating hypertriglyceridemia in a subject, comprising administering to the subject one to four capsules per day, each capsule comprising a pharmaceutical composition comprising docosapentaenoic acid in an amount of up to about 20%, by weight, of all fatty acids in the pharmaceutical composition and about 750 mg to about 950 mg eicosapentaenoic acid, and wherein the pharmaceutical composition comprises substantially no or no docosahexaenoic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019
From: OSTERLOH, IAN; WICKER, PIERRE; BRAECKMAN, RENE; SONI, PARESH; MANKU, MEHAR
To: AMARIN PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 048427/0661 →